A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Recombinant Fully Human Anti-CD39 Monoclonal Antibody JS019 in Patients With Advanced Solid Tumors or Lymphomas
Latest Information Update: 04 Apr 2024
At a glance
- Drugs JS 019 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Kebo Ruijun Biotechnology
Most Recent Events
- 18 May 2022 New trial record